{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:49:13Z","timestamp":1785761353435,"version":"3.56.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Histological transformation is an important mechanism of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in EGFR-mutant non-small cell lung cancer. Compared with small cell transformation, acquired squamous transformation is uncommon and remains less well characterized. We report a 52-year-old woman who underwent thoracoscopic left upper lobectomy and wedge resection of the left lower lobe for lung adenocarcinoma in April 2021. Molecular testing identified an EGFR exon 19 deletion and a TP53 c.713G&amp;gt;T (p.C238F) mutation. She received osimertinib, and the interval from treatment initiation to the first clinically and radiologically suspected disease progression was approximately 39 months. After this clinically suspected progression, pemetrexed plus cisplatin achieved a partial response. In August 2025, an enlarged left supraclavicular lymph node was detected, and re-biopsy confirmed squamous cell carcinoma. Systemic evaluation did not reveal evidence of a second primary malignancy. Molecular testing of the squamous lesion identified the same EGFR exon 19 deletion and TP53 mutation as those in the primary lung adenocarcinoma, providing molecular evidence consistent with a shared tumor origin and favoring acquired squamous histological transformation over a second primary squamous cell carcinoma. The patient subsequently received carboplatin, nanoparticle albumin-bound paclitaxel, and tislelizumab, achieving a radiologic partial response followed by stable disease during maintenance tislelizumab. This case highlights acquired squamous histological transformation as a rare resistance pattern after long-term osimertinib treatment. Re-biopsy and molecular comparison are important for distinguishing histological transformation from a second primary tumor. The observed response to platinum-taxane chemotherapy combined with tislelizumab should be interpreted cautiously because the relative contributions of chemotherapy and immunotherapy cannot be determined from a single case.<\/jats:p>","DOI":"10.3389\/fonc.2026.1911851","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:04:17Z","timestamp":1785758657000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: squamous transformation after long-term osimertinib in EGFR-mutant lung adenocarcinoma with retained EGFR\/TP53 alterations"],"prefix":"10.3389","volume":"16","author":[{"given":"Lina","family":"Xu","sequence":"first","affiliation":[{"name":"Oncology Department of Integrated Traditional Chinese and Western Medicine, Shenyang Tenth People\u2019s Hospital","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shenyang Tenth People\u2019s Hospital","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shenyang Tenth People\u2019s Hospital","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Shenyang Tenth People\u2019s Hospital","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Oncology Department of Integrated Traditional Chinese and Western Medicine, Shenyang Tenth People\u2019s Hospital","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091515","article-title":"Non-small cell lung cancer with epidermal growth factor receptor (EGFR) common mutations: New strategies","volume":"17","author":"Stanzione","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00408-025-00801-x","article-title":"Update 2025: Management of non-small-cell lung cancer","volume":"203","author":"Jeon","year":"2025","journal-title":"Lung"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101266","article-title":"Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer","volume":"82","author":"Du","year":"2025","journal-title":"Drug Resist Update"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27010445","article-title":"Lineage plasticity and histologic transformation in EGFR-TKI resistant lung cancer","volume":"27","author":"Lau","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.883367","article-title":"Long-term clinical benefit in EGFR-mutant lung adenocarcinoma with local squamous cell carcinoma transformation after EGFR TKI resistance: A case report","volume":"12","author":"Ye","year":"2022","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41392-024-01981-3","article-title":"Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomas","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1515\/jtim-2024-0019","article-title":"Histological transformation in lung adenocarcinoma: Insights of mechanisms and therapeutic windows","volume":"12","author":"Tan","year":"2024","journal-title":"J Transl Int Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.942084","article-title":"Transformation of adenocarcinoma to squamous cell carcinoma as a source of EGFR-TKI resistance: A case report and literature review","volume":"12","author":"Xi","year":"2022","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16192","article-title":"Histologic transformation of non-small-cell lung cancer in response to tyrosine kinase inhibitors: Current knowledge of genetic changes and molecular mechanisms","volume":"115","author":"Shiba-Ishii","year":"2024","journal-title":"Cancer Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.06.012","article-title":"Molecular landscape and therapeutic strategies of lung cancer lineage plasticity","volume":"20","author":"Banerjee","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming eighth edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41571-025-01085-z","article-title":"Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches","volume":"23","author":"Zhao","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2017.10.005","article-title":"Squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma: A case report and literature review","volume":"19","author":"Izumi","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.06.026","article-title":"Transformations first into squamous-cell carcinoma and later into sarcomatoid carcinoma after acquired resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma: Case report","volume":"22","author":"Lee","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.lungcan.2019.05.024","article-title":"Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma","volume":"134","author":"Park","year":"2019","journal-title":"Lung Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-3563","article-title":"Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.11.016","article-title":"Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case","volume":"127","author":"Roca","year":"2019","journal-title":"Lung Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2019.12.017","article-title":"Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation","volume":"119","author":"Chiang","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.696881","article-title":"Case report: EGFR-positive early-stage lung adenocarcinoma transforming to squamous cell carcinoma after TKI treatment","volume":"11","author":"Liao","year":"2021","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s513879","article-title":"A rare histologic transformation from EGFR-positive lung adenocarcinoma to EGFR-negative squamous cell carcinoma after EGFR-TKIs resistance: A case report","volume":"18","author":"Qiu","year":"2025","journal-title":"Onco Targets Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1038\/s41467-025-59623-3","article-title":"Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma","volume":"16","author":"Shinozaki","year":"2025","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189413","article-title":"Histological transformation in lung cancer: Mechanisms, clinical characteristics, and therapeutic approaches","volume":"1880","author":"Liu","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2022.02.006","article-title":"Histologic transformation of epidermal growth factor receptor-mutated lung cancer","volume":"166","author":"Fujimoto","year":"2022","journal-title":"Eur J Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.1038\/s41598-022-10288-8","article-title":"Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC","volume":"12","author":"Koyama","year":"2022","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6870","article-title":"Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancer","volume":"13","author":"Lin","year":"2024","journal-title":"Cancer Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/crj.13705","article-title":"Study on the application of percutaneous closed pleural brushing combined with cell block technique in the diagnosis of Malignant pleural effusion","volume":"18","author":"Wang","year":"2024","journal-title":"Clin Respir J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102602","article-title":"Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review","volume":"119","author":"Attili","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00379-6","article-title":"Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis","volume":"25","author":"Zhao","year":"2024","journal-title":"Lancet Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(23)00135-2","article-title":"Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): Second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Respir Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1911851\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:04:20Z","timestamp":1785758660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1911851\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":31,"alternative-id":["10.3389\/fonc.2026.1911851"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1911851","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"article-number":"1911851"}}